Eisai acquires domestic approval of ‘Lenvima,’ thyroid cancer treatment
Eisai Korea(President Hong-byung Ko) announced Eisai, a global pharmaceutical company, has acquired approval for its newly developed antibiotics, ‘Lenvima Cap(generic name: lenvatinib),’ as treatment of progressive differentiated thyroid cancer which is resisted to radioactive iodine, recurrence ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
